247 related articles for article (PubMed ID: 27811123)
21. Initial [18F]FDG PET/CT in high-risk DTC patients. A three-year follow-up.
Ruhlmann M; Binse I; Bockisch A; Rosenbaum-Krumme SJ
Nuklearmedizin; 2016 Jun; 55(3):99-103. PubMed ID: 26830084
[TBL] [Abstract][Full Text] [Related]
22. Differential roles of 18F-FDG PET in patients with locoregional advanced nasopharyngeal carcinoma after primary curative therapy: response evaluation and impact on management.
Chan SC; Yen TC; Ng SH; Lin CY; Wang HM; Liao CT; Fan KH; Chang JT
J Nucl Med; 2006 Sep; 47(9):1447-54. PubMed ID: 16954552
[TBL] [Abstract][Full Text] [Related]
23. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
24. Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment.
Nasu K; Abe W; Takai N; Tomonari K; Narahara H
Arch Gynecol Obstet; 2011 May; 283(5):1121-6. PubMed ID: 20574659
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG PET/CT Is an Immediate Imaging Biomarker of Treatment Success After Liver Metastasis Ablation.
Cornelis F; Sotirchos V; Violari E; Sofocleous CT; Schoder H; Durack JC; Siegelbaum RH; Maybody M; Humm J; Solomon SB
J Nucl Med; 2016 Jul; 57(7):1052-7. PubMed ID: 26912433
[TBL] [Abstract][Full Text] [Related]
26. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
[TBL] [Abstract][Full Text] [Related]
27. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
28. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
[TBL] [Abstract][Full Text] [Related]
29.
Han EJ; O JH; Yoo IR; Kim YS; Kim MS; Kang JH; Choi WH
Hell J Nucl Med; 2017; 20(2):134-140. PubMed ID: 28697190
[TBL] [Abstract][Full Text] [Related]
30. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
31. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
32. FDG PET/CT imaging of desmoplastic small round cell tumor: findings at staging, during treatment and at follow-up.
Ostermeier A; McCarville MB; Navid F; Snyder SE; Shulkin BL
Pediatr Radiol; 2015 Aug; 45(9):1308-15. PubMed ID: 25721584
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis.
Goense L; van Rossum PS; Reitsma JB; Lam MG; Meijer GJ; van Vulpen M; Ruurda JP; van Hillegersberg R
J Nucl Med; 2015 Jul; 56(7):995-1002. PubMed ID: 25952733
[TBL] [Abstract][Full Text] [Related]
34. Early detection of disease progression after palliative chemotherapy in NSCLC patients by (18)F-FDG-PET.
Tauhardt E; Reissig A; Winkens T; Freesmeyer M
Nuklearmedizin; 2014; 53(5):197-204. PubMed ID: 24986272
[TBL] [Abstract][Full Text] [Related]
35. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
[TBL] [Abstract][Full Text] [Related]
36. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic value of
Kassem TW; Abdelaziz O; Emad-Eldin S
Diagn Interv Imaging; 2017 Oct; 98(10):693-698. PubMed ID: 28734778
[TBL] [Abstract][Full Text] [Related]
38. FDG PET-CT in pediatric Langerhans cell histiocytosis.
Jessop S; Crudgington D; London K; Kellie S; Howman-Giles R
Pediatr Blood Cancer; 2020 Jan; 67(1):e28034. PubMed ID: 31599488
[TBL] [Abstract][Full Text] [Related]
39. The value of follow-up FDG-PET/CT in the management and prognosis of patients with HPV-positive oropharyngeal squamous cell carcinoma.
Taghipour M; Marcus C; Califano J; Fakhry C; Subramaniam RM
J Med Imaging Radiat Oncol; 2015 Dec; 59(6):681-6. PubMed ID: 26768092
[TBL] [Abstract][Full Text] [Related]
40. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
